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Abstract
Background:  Inflammation is associated with increased resting energy expenditure (REE) in
patients with chronic kidney disease. Oxidative stress, on the other hand, appears not to increase
REE. Smoking is a common mechanism for generating oxidative stress and inflammation. Whether
smokers have increased REE and if so, whether it is accounted for by the pro-oxidant and
inflammatory state is not known.
Methods:  A case control study of 11 smokers and 24 non-smokers with overt diabetic
nephropathy was performed to evaluate the chronic effect of smoking on REE. REE (indirect
calorimetry), glomerular filtration rate (iothalamate clearance), markers of oxidative stress (urinary
and plasma malondialdehyde (MDA), and protein carbonyls) and inflammation (C-reactive protein,
tumor necrosis factor-alpha, interleukin-6) were measured on two occasions four months apart.
Results: Biomarkers of inflammation (C-reactive protein) and oxidative stress (urinary and plasma
MDA) were increased in smokers. REE was increased in smokers, 24.3 kcal/kg/day compared to 21
kcal/kg/day (p = 0.009) in non-smokers. After adjusting for age, GFR, MDA, C-reactive protein, and
hemoglobin A1C the difference in REE between the two groups persisted (adjusted difference 3.51
kcal/kg/d, 95% confidence interval 0.59 – 6.45, p = 0.020).
Conclusion: Patients with overt diabetic nephropathy who smoke have a higher REE, oxidative
and inflammatory state. Elevated REE is not attributable to heightened oxidative stress and
inflammatory state. Smoking is an independent risk factor for elevated REE in patients with diabetic
nephropathy and provides an additional mechanism by which it may lead to poor outcomes.
Background
Diabetic nephropathy is the commonest cause of end-
stage renal disease (ESRD). Malnutrition in patients with
ESRD is associated with increased morbidity and mortal-
ity. Nutritional decline begins long before patients with
progressive CKD become dialysis dependent [1,2] which
in part is related to the spontaneous reduction in dietary
protein and caloric intake with reduction in glomerular
filtration rate (GFR) [3-8].
Recent studies point out that chronic subclinical inflam-
mation in patients with CKD is associated with an
increase in REE [9]. Other studies, done in patients with-
out CKD, show that oxidative stress is not associated with
increase in REE [10]. Smoking is associated with both an
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increase in oxidative stress and subclinical inflammation,
thus serves as a model to study the effect of oxidative-
inflammatory state on REE [11]. Smoking may therefore
compound the oxidative stress and the inflammatory state
in patients with CKD [2,12-14]. Whether smoking-
induced oxidative-inflammatory state is sufficient to
account for elevated REE is not known.
Although smoking-induced increase REE is thought to be
acute and transient – in part due to nicotine-induced sym-
pathoadrenal activation – more recent studies point to a
chronic elevation in REE [15]. In epidemiological studies,
increased REE is seen in young women who smoke com-
pared to women who do not, even after controlling for
differences in body size and overnight abstinence from
smoking [16]. Smoking cessation often leads to weight
gain [17]. Thus, smoking may accelerate malnutrition via
accelerating attrition in renal function in addition to ele-
vating REE.
In this study we asked the question whether smokers with
diabetic nephropathy have an increased REE compared to
non-smokers with equally severe diabetic nephropathy. If
so, is the increased REE mediated by the pro-oxidant and
inflammatory state.
Methods
Subjects
Thirty-five clinically stable Veterans with diabetic neph-
ropathy were recruited from the Renal Clinic of the
Roudebush VA Medical Center, Indianapolis, IN after
review and approval of protocol by the Institutional
Review Board of Indiana University and VA Research and
Development Committee. Signed written informed con-
sent was obtained from each participant.
Patients with type 2 diabetes requiring treatment with oral
hypoglycemic drugs or insulin, were required to have a
urine protein/creatinine ratio of >1.0 g/g on a single
voided specimen and a creatinine clearance of >20 mL/
min by Cockcroft-Gault formula. All patients were partic-
ipating in a randomized clinical trial examining the influ-
ence of pioglitazone compared to glipizide on reduction
of proteinuria. Exclusion criteria included the presence of
liver disease, NYHA Class III or IV heart failure, unstable
angina, myocardial infarction or stroke in the previous 3
months, NSAID use, or body mass index of ≥40 kg/m2.
Patients underwent a standardized history and physical
examination that included assessment of medications and
control of diabetes mellitus by hemoglobin A1C. Current
smoking status was ascertained by a yes or no response.
The following measurements were made in 32 of 35 sub-
jects on two occasions four months apart; in the remain-
ing three only one measurement was made:
Glomerular filtration rate
GFR was measured by iothalamate clearance using a con-
tinuous subcutaneous infusion at a rate of 125 µL/hour
that was started after a bolus intravenous injection 24
hour prior to actual measurements [18]. The following
day, six samples of plasma were collected at times 0, 1.0,
1.5, 2.0, 2.5 and 3.0 hours while the subjects were water
loaded. Plasma iothalamate concentrations were analyzed
using a previously reported high-performance liquid
chromatography technique [19]. The ratio of infusion rate
to steady-state plasma concentration yielded the iothala-
mate clearance. The average of these six collections was
expressed as the GFR.
Resting energy expenditure
Seated measurements were made in the morning after an
overnight fast. Subjects were asked not to drink or eat any-
thing and refrain from smoking after midnight. They were
asked only take half the usual dose of insulin if they were
on insulin. Two indirect calorimetric measurements were
made 4 months apart in 32 patients and one measure-
ment in the remaining 3 patients.
REE was calculated using open circuit indirect calorimetry
in a computerized metabolic system; the gas concentra-
tions of O2 and CO2 were measured in real time using as
gas mass-spectrophotometer (Marquette Electronics, Inc,
Milwaukee, WI) connected to a computer. The flow rate of
the inhaled and exhaled air was simultaneously measured
using a flow meter, interfaced to an analog to digital con-
version board with data sampled at 20 Hz and stored to a
memory file. The data was analyzed using First Breath
Software (First Breath Inc., Ontario, Canada) to calculate
oxygen consumption and carbon dioxide production in
mL/min. The modified Weir's equation (REE (Kcal/day) =
[VO2 mL/min (3.94) + VCO2 mL/min (1.11)] × 1.44) [20]
was used to calculate the REE. Data were collected for 30
minutes and for the purposes of analysis the first 5 min-
utes of the collection were discarded since they did not
represent steady state.
Lean body mass
To relate REE to differences in body composition between
smokers and non-smokers, lean body mass was measured
by anthropometric and body impedance spectroscopy.
Anthropometric method
Skinfold thickness measurements were taken in triplicate
for biceps, triceps, subscapular and supra-iliac areas by a
single observer using Lange skin-fold calipers (Beta Tech-
nology Inc, Cambridge, MD, USA) and lean body mass
(FFM SFT) was calculated by Durnin and Womersley for-
mula [21].BMC Nephrology 2005, 6:13 http://www.biomedcentral.com/1471-2369/6/13
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Body impedance spectroscopy
Body composition was measured using bioelectric imped-
ance analysis (BIA). A BIA-106 Spectrum II analyzer (RJL
Systems, Inc., Clinton Twp. MI) was used and data was
collected using Weight Manager Version 2.0 software (RJL
Systems, Inc., Clinton Twp. MI). The technique of BIA
involved introducing an imperceptible 800 µA alternating
current at 50 kHz through signal introduction cables
placed with pre-gelled electrodes on the ulnar head and
medial malleolus. Sensing electrodes placed at the ipsilat-
eral 3rd metacarpal and 2nd metatarsal, determined the
electrical resistance and reactance. Lean body mass was
calculated from estimates of total body potassium.
Protein nitrogen appearance
Two 24-hour urine samples were collected for the meas-
urement of creatinine, urea, sodium, potassium, chloride
and protein. The average of the two 24-hour excretion
rates was used for analyses. Dietary protein intake was
estimated from the urea nitrogen appearance rate (UNA),
calculated as follows [22]: Protein intake (g/day) =
6.25[urine urea nitrogen (UUN) (g/day) + 0.031 × body
weight(kg)]
Oxidative stress markers
Malondialdehyde (MDA)
Malondialdehyde (MDA), a lipid hydroperoxide, is
formed by β-scission of peroxidized polyunsaturated fatty
acids and was measured by high performance liquid chro-
matography following derivatization with thiobarbituric
acid (TBA) as reported previously [23]. Urinary MDA was
analyzed in three spontaneously voided specimens over a
period of 3 hours. Each specimen was analyzed for MDA
and creatinine. The MDA/creatinine ratio was averaged
and used further for statistical analysis. Blood was col-
lected in tubes containing EDTA at first and last visits.
Plasma was separated by centrifugation and stored at -
84°C until analysis
Carbonyl measurements
Oxidation of plasma and urine proteins were measured by
analysis of Western blots with slight modifications of a
previous report [24]. Total protein was determined using
bicinchoninic acid (BCA-1 Protein Assay Kit, Sigma, St.
Louis). Urine protein was measured by the dye binding
method using a complex of pyrogallol red and molybde-
num acid (QuanTtest Red Total Protein Assay System,
Quantimetrix, Redondo Beach, CA). Plasma was diluted
1:25 (v:v) with phosphate-buffered saline (PBS), one aliq-
uot of the diluted sample was derivatized and another pre-
pared as an underivatized control using the OxyBlot
protein oxidation detection kit (Intergen, Purchase, NY,
USA) Urine samples were derivatized with dinitro phenyl
hydrazine (DNP) or control reagent similarly except that
samples were not diluted prior. Derivatized and underiva-
tized plasma or urine samples were loaded on electro-
phoresis gels in volumes calculated to give 5 µg protein
per sample and electrophoresed according to the method
Table 1: Clinical and Laboratory Characteristics of Patients with Type 2 Diabetic Nephropathy
Parameter Non-smokers Mean ± SD or N (%) Smokers Mean ± SD or N (%)
N2 4 1 1
Age (y) 69.1 ± 7.0 61.5 ± 9.3 *
Males/Females 24/0 11/0
Race White/Black 19/5 9/2
Weight (kg) 97.8 ± 16.8 102.5 ± 23.4
BMI (kg/m2) 32.6 ± 4.9 32.6 ± 6.6
Serum albumin (g/dL) 3.8 ± 0.33 3.63 ± 0.30
Serum Creatinine (mg/dL) 2.75 ± 1.21 1.80 ± 0.74 *
BUN (mg/dL) 46.5 ± 25.6 38.3 ± 21.8
Hemoglobin (g/dL) 13.3 ± 1.6 13.5 ± 2.4
24 hour urine protein (g/d) 3393 ± 2522 4423 ± 4385
Iothalamate clearance (GFR) (mL/min/1.73 m2) 28.9 ± 13.8 47.2 ± 34.8 *
Duration of diabetes (yr) 15.7 ± 9.1 13.3 ± 9.0
Insulin use 15 (63%) 6 (55%)
Hemoglobin A1C (%) 7.57 ± 2.02 8.98 ± 2.93
Waist/Hip Ratio 1.00 ± 0.07 1.04 ± 0.07
Antihypertensive medications 4.3 ± 1.6 3.9 ± 1.9
ACE inhibitor or Angiotensin receptor blocker use 21 (88%) 8 (73%)
Total Cholesterol (mg/dL) 184 ± 51 223 ± 87
LDL Cholesterol (mg/dL) 100 ± 44 116 ± 24
HDL Cholesterol (mg/dL) 42 ± 11.1 46 ± 11.4
Vascular Disease (coronary, cerebrovascular or peripheral vascular disease) 17 (71%) 7 (64%)
* p < 0.05BMC Nephrology 2005, 6:13 http://www.biomedcentral.com/1471-2369/6/13
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of Laemmli on 4 to 20%gradient SDS-PAGEgels (Bio-Rad,
Hercules, CA, USA) for 60 minutes at 200 V. Following
electroblotting to 0.2 µ nitrocellulose for 60 volt hours,
the membrane was blocked with subsequent immunob-
lotting using OxyBlot Kit methods and reagents. Bands
were visualized with chemiluminescence and captured on
film and analyzed densitometrically using dedicated soft-
ware using a GelLogic 100 System (Kodak, Rochester,
NY).
Samples for individual patients before and after therapy
(glipizide or pioglitazone), including derivatized and
underivatized control, were analyzed on a single Western
blot to ensure that responses to therapy were compared
under the same analytical conditions. The blot was
stained for protein with amido black and the ratio of the
density of the carbonyl band vs the corresponding protein
band was used to calculate the percent carbonylation of
total protein and comparisons before and after therapy
made. The carbonyl band corresponding to the molecular
weight of albumin was also compared to the correspond-
ing amido black band to generate a ratio to assess the pro-
portion of albumin oxidized.
Inflammation markers
Total leukocyte count (WBC count)
Blood was collected in EDTA containing vacutainers
(Beckton-Dickinson) and total leukocyte count calculated
by the Coulter method (Coulter STK-S, Coulter Electron-
ics, Inc., Hialeah, FL) by our clinical laboratory.
C-reactive Protein (CRP)
CRP was measured by Cobas Integra 400 autoanalyzer
using a particle enhanced turubidimetric assay (Cobas
Integra C-Reactive Protein Latex, Roche Diagnostics, Indi-
anapolis, IN). The intra-assay coefficient of variation was
1.8% and the inter-assay coefficient of variation was 2.9%
at a mean level of 0.62 mg/dL CRP.
Interleukin 6 (IL-6)
Interleukin 6 (IL-6) was assayed in plasma using a sand-
wich ELISA (Quantikine®  kit for Human IL-6 Immu-
noassay; R&D Systems, Minneapolis, MN). A standard
curve was generated using a linear curve-fit. The correla-
tion coefficient for standards was greater than 0.99 and
the lowest detectable limit 0.039 pg/ml in undiluted
plasma. The intra-assay coefficient of variation was 7.8%
and the inter-assay coefficient of variation was 7.2%.
Tumor Necrosis Factor-α (TNF-α)
Tumor Necrosis Factor-α (TNF-α) was assayed in plasma
using a sandwich ELISA (Quantikine® kit for Human TNF-
α Immunoassay; R&D Systems, Minneapolis, MN). A
standard curve was generated using a linear curve-fit. The
correlation coefficient for standards was greater than 0.99
and the lowest detectable limit 0.12 pg/ml in undiluted
plasma. The intra-assay coefficient of variation was 5.9%
and the inter-assay coefficient of variation was 12.6%.
Urinary Monocyte Chemotactic Protein-1 (MCP-1)
MCP1 was assayed in urine using a sandwich ELISA
(Quantikine® kit for Human MCP1 Immunoassay; R&D
Systems, Minneapolis, MN). Corrections were made for
concentration and values expressed as pg MCP1 per mg
creatinine. A standard curve was generated using a four
parameter logistic curve-fit. The correlation coefficient for
standards was greater than 0.99 and the lowest detectable
limit 0.7 pg/ml in 1:2 diluted urine. The intra-assay coef-
ficient of variation was 2.5 ± 3.0% and the inter-assay
coefficient of variation was 5.6 ± 4.2%.
Table 2: Body Composition Analysis by Body Impedance Spectroscopy and Skin Fold Thickness
Parameter Non-Smokers N = 24 Smokers N = 11
Body Weight (kg) 99.2 (91.5 – 106.9) 101 (89.6 – 112.4)
Phase angle 5.70 (4.46 – 6.93) 5.12 (3.30 – 6.94)
Vector length 227 (210 – 244) 202 (177 – 227)
Fat free mass (kg) 74.4 (68.2 – 80.6) 81.5 (72.4 – 90.6)
Total body water (L) 55.3 (50.9 – 59.8) 60.6 (54.1 – 67.1)
Fat mass (kg) 25.4 (20.1 – 30.7) 21.3 (13.5 – 29.0)
Total body potassium (mEq) 3981 (3650 – 4313) 4130 (3641 – 4618)
Body cell mass (kg) 33.2 (30.4 – 35.9) 34.4 (30.3 – 38.5)
Extracellular mass (kg) 41.3 (36.4 – 46.1) 46.9 (39.8 – 54.1)
Intracellular water (L) 30.3 (27.7 – 32.8) 31.4 (27.7 – 35.1)
Extracellular water (L) 25.1 (21.6 – 28.5) 29.0 (23.9 – 34.1)
Fat free mass from Skin fold thickness (kg) 53.4 (50.2 – 56.6) 56.4 (51.6 – 61.2)
Least square mean values with 95% confidence intervals are calculated from the mixed model ANOVA model as described in methods. None of the 
comparisons were significantly different between the groups.BMC Nephrology 2005, 6:13 http://www.biomedcentral.com/1471-2369/6/13
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Statistical analysis
Differences in baseline characteristics were compared by a
Chi-squared or unpaired t-test. To determine the relation-
ship between smoking status and REE a mixed model
ANOVA was used to account for correlated observations
within subject. The dependent variable was REE/kg body
weight; smoking status was used as the fixed effect varia-
ble and the subject number as the random effect variable.
Clinical, oxidative stress and inflammation markers were
used as covariates as noted. The adjusted least square
means and 95% confidence intervals obtained form this
ANOVA model are reported. SPSS for Windows (version
13, SPSS, Chicago, IL) was used for all analyses. Two sided
p-value of less than 0.05 was taken as significant.
Results
The clinical and laboratory characteristics of the study
population are presented in Table 1. In keeping with a
diagnosis of diabetic nephropathy, the population was
obese, required multiple drugs for treatment of hyperten-
sion and had a high prevalence of vascular disease. Smok-
ers and non-smokers were well matched, except in that
smokers were younger and had higher baseline glomeru-
lar filtration rate.
Body composition, as measured by body impedance spec-
troscopy and skin-fold thickness assessment, was no dif-
ferent between smokers and non-smokers (Table 2).
Table 3 shows markers of oxidative stress, inflammation,
and other metabolic parameters. Plasma and urinary
MDA were significantly increased in smokers reflecting
the heightened state of oxidative stress. However, protein
oxidation markers were similar in the two groups. C-reac-
tive protein was also significantly increased in smokers,
reflecting the inflammatory state. Plasma interleukin-6
was marginally higher in smokers, however tumor necro-
sis factor-α did not reach statistical significance. Urine
MCP-1 excretion was nearly equal in smokers and non-
smokers. Thyroid stimulating hormone reflecting the
overall metabolic state was also no different between the
smokers and non-smokers. GFR was significantly higher
in smokers at 46.7 mL/min/1.73 m2 compared to non-
smokers at 29.1 mL/min/1.73 m2.
Body weight is an important determinant of REE in smok-
ers and non-smokers (Figure 1). For any given weight,
smokers had a higher REE compared to non-smokers.
Unadjusted increase in REE was 3.26 kcal/kg/d in smokers
Table 3: Comparison of REE, Inflammation and Oxidative Stress Markers in Smokers and Non-smokers
Parameter Non-smokers Smokers Difference (Smokers – 
non-smokers)
p
REE/kg body wt. 21.0 (19.7 – 22.3) 24.3 (22.3 – 26.2) 3.26 (0.87 – 5.6) 0.009
Respiratory Quotient 0.85 (0.83 – 0.87) 0.81 (0.78 – 0.85) NS
Oxidative Stress Makers
Plasma malondialdehyde (µM/L) 0.94 (0.79 – 1.08) 1.20 (0.98 – 1.41) 0.26 (0.0 – 0.52) 0.05
Urine malondialdehyde/urine creatinine ratio 
(µM/g creatinine)
3.36 (2.44 – 4.28) 6.33 (4.95 – 7.72) 2.97 (1.31 – 4.64) 0.001
Plasma total carbonyl (DU) 0.818 (0.728 – 0.908) 0.791 (0.658 – 0.924) NS
Urine total carbonyl (DU) 0.454 (0.336 – 0.571) 0.444 (0.270 – 0.617) NS
Plasma albumin carbonyl (DU) 1.425 (1.278 – 1.572) 1.441 (1.225 – 1.658) NS
Urine albumin carbonyl (DU) 0.598 (0.438 – 0.758) 0.591 (0.356 – 0.827) NS
Inflammation Markers
White blood cell count (number/µL) 7897 (6885 – 8908) 9139 (7647 – 10,631) NS
C-reactive protein (mg/dL) 0.80 (0.37 – 1.23) 1.77 (1.13 – 2.40) 0.97 (0.21 – 1.74) 0.014
Interleukin-6 (pg/mL) 2.13 (1.48 – 2.78) 3.28 (2.31 – 4.25) 1.15 (-0.02 – 2.32) 0.053
Tumor necrosis factor-α (pg/mL) 4.05 (3.05 – 5.05) 3.89 (2.40 – 5.38) NS
MCP-1/Creatinine (pg/mg) 398 (288 – 508) 399 (228 – 569) NS
Other variables
HbA1C (%) 7.46 (6.64 – 8.27) 8.73 (7.52 – 9.94) NS
Plasma glucose (mg/dL) 132 (110 – 153) 168 (136 – 200) NS
Protein nitrogen appearance rate (g/kg/d) 0.76 (0.68 – 0.83) 0.81 (0.71 – 0.92) NS
Iothalamate clearance (mL/min/1.73 m2) 29.1 (19.6 – 38.6) 46.7 (32.7 – 60.6) 17.6 (0.7 – 34.6) 0.042
24 hour urine protein (mg/d) 3384 (2180 – 4588) 4189 (2410 – 5967) NS
Thyroid stimulating hormone 2.32 (1.87 – 2.78) 2.04 (1.37 – 2.71) NS
Values reported are least square mean values with 95% confidence intervals are calculated from the mixed model ANOVA model as described in 
methods. DU stands for densitometric units, REE for resting energy expenditure, MCP-1 for monocyte chemotactic protein-1.BMC Nephrology 2005, 6:13 http://www.biomedcentral.com/1471-2369/6/13
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compared to non-smokers (p = 0.009). When adjusted for
baseline differences in age, GFR, the oxidative stress mark-
ers MDA in urine and plasma, and C-reactive protein did
not diminish the elevated REE attributable to smoking
(Table 4).
There was no independent relationship between MDA/
creatinine ratio and REE (partial correlation coefficient =
0.163 (p = 0.19)) or between CRP and REE (partial corre-
lation coefficient = 0.177, (p = 0.16)) after accounting for
correlated measurements. None of the other markers of
inflammation or oxidative stress achieved statistical sig-
nificance.
Discussion
The major finding of this study is that patients with dia-
betic nephropathy who smoke have an elevated REE after
accounting for body weight – the strongest single predic-
tor of REE [25-27]. Smokers had a heightened state of oxi-
dative stress and inflammation. However, neither
biomarkers of oxidative stress, nor inflammation had an
independent relationship with REE. Furthermore, the
association of smoking and elevated REE was not
removed when markers of oxidative stress and inflamma-
tion were accounted for, strengthening the possibility that
oxidative stress and inflammation markers by themselves
are insufficient to account for elevated REE in smokers
with diabetic nephropathy.
That oxidative stress by itself has little role in elevating
REE has been demonstrated in the elderly without kidney
disease [10] Our study supports these observations and
extends this to patients with CKD.
The relationships between inflammation, creatinine clear-
ance, and REE have been analyzed by Avesani et al in a
cross-sectional study of in 91 non-dialyzed patients with
CKD [9]. Consideration of kidney function is important
for evaluating REE because the oxygen consumption of
the kidneys is high – estimated to be between 5.6% and
20% of the total metabolic rate [28,29] – and failing kid-
neys may have reduced oxygen consumption contributing
to reduced REE [29,30]. REE may also decrease as an adap-
tation to the decreased energy intake or accumulation of
uremic toxins that depresses metabolic activity. However,
studies are not conclusive regarding this observation.
Whereas some studies have shown decreased [31,32] REE
others have shown no change [33] or even increased [34]
REE in CKD. Avesani et al did not find any relationship
between quartiles of creatinine clearance and REE but they
Resting energy expenditure is plotted against body weight Figure 1
Resting energy expenditure is plotted against body weight. A linear relationship is seen for smokers and non-smokers. Inset 
shows that the mean unadjusted REE in smokers is higher by 3.26 kcal/kg/day (p = 0.009)
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were amongst the first to propose inflammation as a cause
of elevated REE in CKD [35]. Those in the highest tertile
of CRP – and accordingly most inflamed – had an unad-
justed REE that was higher compared to the lower tertiles
of CRP. Consideration of smoking status as a cause of
raised REE has not been reported in any of the above stud-
ies. It is possible that the association of increased CRP
with REE may simply be due to overrepresentation by
smokers in the highest tertile of CRP. Our study suggests
consideration of smoking as a covariate in analyses of REE
in patients with CKD.
Given that GFR can have a variable influence on REE, as
noted above, it is important to account for the effect of
GFR in studies dealing with REE in patients with CKD.
Smokers in this study had a statistically increased GFR
compared to non-smokers which is similar to what has
been reported for a large population based study from
France [36]. However, adjustment for GFR did not remove
the effect of smoking to elevate REE. Other adjustments,
such as that for age, CRP, urine and plasma MDA also did
not remove the association of increased REE with smok-
ing. Thus, other unmeasured factors may account for the
elevated REE in smokers.
The effect of cigarette smoking on REE are thought to be
acute and transient and related to sympathetic activation
[15]. It should be noted that this study did not examine
the acute effect of smoking, rather the chronic effect of
smoking. The large effect of smoking on REE was some-
what unexpected. In one epidemiologic study, women
who smoked had a statistically significant increase in REE
[16]. The magnitude of the effect of smoking was 68 kcal/
d which was approximately one-third of the effect size
reported in the present study [16]. In another study, black
women who smoked were found to have a greater base-
line REE compared to white women [37]. Specifically,
amongst black women, heavy smoking was associated
with 218 kcal/d higher REE and moderate smoking with
177 kcal/d higher REE compared to non-smokers.
Although studies on the effect of smoking in diabetic
nephropathy or those with CKD have not been reported,
the results of this study are in line with those reported by
others in populations without CKD [16,37] and extend
these observations to patients with CKD. Exactly how
chronic smoking leads to increased REE is not clear from
present investigations [38].
There are some limitations of this study. First, the sample
size was relatively small and limited to men. Nevertheless,
repeated observations in the same patient improved the
precision of the measurements and demonstrated a highly
significant difference between smokers and non-smokers.
Second, diabetes control was less than optimal in some
patients that can elevate resting energy expenditure by
itself. However, adjustment for diabetes control did not
mitigate the significance of the results. Third, we did not
quantify the amount and duration of smoking that may
have an independent effect on REE [37]. Finally, these
data may not be applicable to women.
In summary, this study demonstrates higher REE in smok-
ers with diabetic nephropathy after adjusting for body
weight. These findings generate the hypothesis that smok-
ers with diabetic nephropathy would be most prone to
protein-energy malnutrition at the onset of ESRD and add
to other health-risks of smoking in this popula-
tion[31,33,34,39]. Aside from increasing REE, smoking is
known to suppress appetite, which given the anorexic
state of uremia, can produce malnutrition by two ways –
lowering intake and increasing energy expenditure. Smok-
ing should be considered as a cause of increased REE in
patients with CKD when analyzing the effect of other var-
iables such as inflammation and GFR. Longitudinal stud-
Table 4: Increase in resting energy expenditure in unadjusted and adjusted models associated with smoking
Adjusted variable Resting Energy 
Expenditure (kcal/kg/d)
95% confidence interval of 
the estimate
P value
None (Unadjusted model) 3.26 0.87 – 5.6 0.009
Age 3.70 1.05 – 6.35 0.008
Age + GFR 3.67 0.94 – 6.40 0.01
Age + GFR + Urine MDA/Cr 3.95 1.06 – 6.84 0.009
Age + GFR + Urine MDA/Cr + CRP 3.71 0.74 – 6.69 0.016
Age + GFR + Urine MDA/Cr + CRP + Plasma MDA 3.48 0.57 – 6.39 0.021
Age + GFR + Urine MDA/Cr + CRP + Plasma MDA + HbA1C 3.51 0.59 – 6.45 0.020
Adjustment for covariates are evaluated at the means which were age = 66.7 years, GFR = 35.6 mL/min/1.73 m2, Urine MDA/Cr = 4.3 µmol/g, 
Plasma MDA 1.03 µmol/L, CRP = 1.00 mg/dL, HbA1C = 7.78%.BMC Nephrology 2005, 6:13 http://www.biomedcentral.com/1471-2369/6/13
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ies are required to better define the complex relationship
between REE, falling renal function, oxidative stress and
inflammation in patients with CKD.
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